/ THE ASSOCIATION OF COMMON GST POLYMORPHISMS WITH INFLAMMATORY AND MULTIORGAN IMPAIRMENT BIOMARKERS IN COVID-19

  • Djurdja Jerotić
  • Ana Krunić
DOI: https://doi.org/10.5937/mp74-39841
Keywords: COVID-19, oxidative stress, glutathione S-transferases, polymorphism

Abstract


Introduction: Due to the established role of oxidative stress in the pathophysiology of COVID-19, it has been proposed that inter-individual differences in patients’ clinical manifestations might be affected by variations in genes encoding antioxidant enzymes, such as glutathione S-transferases (GSTs).

Aim: The aim of this study was to assess the association of polymorphisms in cytosolic GSTs (GSTA1 rs3957357,  GSTM3 rs1332018  and GSTP1 rs1695) with inflammatory parameters (leukocytes, lymphocytes, monocytes, CRP, fibrinogen, ferritin) and multiorgan impairment biomarkers (urea, creatinine, AST, ALT, LDH) in  COVID-19 patients at two time points.

Materials and Methods: GSTM3, GSTA1 and GSTP1 genotypes were determined in 150 COVID-19 patients by appropriate PCR methods.  

Results:  Inflammatory biomarkers (leukocytes, lymphocytes, monocytes) increased 7 days upon admission to the hospital (p<0.001), while CRP and fibrinogen decreased (p<0.001). Out of five analysed multiorgan impairment biomarkers, only urea increased significantly 7 days upon admission (p<0.007), while AST showed statistically significant drop (p<0.001). COVID-19 patients homozygous for variant GSTM3*C/C genotype had increased levels of inflammatory biomarkers such as CRP, fibrinogen and ferritin, but the borderline significance was observed only for fibrinogen (p=0.057). COVID-19 patients homozygous for variant GSTM3*C allele had the highest levels of ALT (p=0.021) and LDH (p=0.045) upon admission.  

Conclusion: Our results on the association between GSTM3 variant genotype with parameters of systemic inflammation and liver damage in COVID-19 patients can contribute to further understanding of pathophysiological mechanisms underpinning this disease, as well as early recognition of COVID-19 patients prone to worse course of the disease.

References


  1. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427.

  2. Iwasaki M, Saito J, Zhao H, Sakamoto A, Hirota K, Ma D. Inflammation triggered by SARS-CoV-2 and ACE2 augment drives multiple organ failure of severe COVID-19: molecular mechanisms and implications. Inflammation. 2021;44(1):13–34.

  3. Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med. 2020;46(8):1603–6.

  4. Gibson PG, Qin L, Puah SH. COVID‐19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre‐COVID‐19 ARDS. Med J Aust. 2020;213(2):54–6.

  5. Fernandes IG, De Brito CA, Dos Reis VMS, Sato MN, Pereira NZ. SARS-CoV-2 and other respiratory viruses: What does oxidative Stress have to do with it? Oxid Med Cell Longev. 2020;2020.

  6. Miripour ZS, Sarrami-Forooshani R, Sanati H, Makarem J, Taheri MS, Shojaeian F, et al. Real-time diagnosis of reactive oxygen species (ROS) in fresh sputum by electrochemical tracing; correlation between COVID-19 and viral-induced ROS in lung/respiratory epithelium during this pandemic. Biosens Bioelectron. 2020;165:112435.

  7. Kosanovic T, Sagic D, Djukic V, Pljesa-Ercegovac M, Savic-Radojevic A, Bukumiric Z, et al. Time Course of Redox Biomarkers in COVID-19 Pneumonia: Relation with Inflammatory, Multiorgan Impairment Biomarkers and CT Findings. Antioxidants. 2021;10(7):1126.

  8. Muhammad Y, Kani YA, Iliya S, Muhammad JB, Binji A, El-Fulaty Ahmad A, et al. Deficiency of antioxidants and increased oxidative stress in COVID-19 patients: A cross-sectional comparative study in Jigawa, Northwestern Nigeria. SAGE open Med. 2021;9:2050312121991246.

  9. Tew KD, Townsend DM. Glutathione-s-transferases as determinants of cell survival and death. Antioxid Redox Signal. 2012;17(12):1728–37.

  10. Menon D, Innes A, Oakley AJ, Dahlstrom JE, Jensen LM, Brüstle A, et al. GSTO1-1 plays a pro-inflammatory role in models of inflammation, colitis and obesity. Sci Rep. 2017;7(1):1–15.

  11. Pljesa-Ercegovac M, Savic-Radojevic A, Matic M, Coric V, Djukic T, Radic T, et al. Glutathione transferases: potential targets to overcome chemoresistance in solid tumors. Int J Mol Sci. 2018;19(12):3785.

  12. Saadat M. The morbidity and mortality of COVID-19 are correlated with the Ile105Val glutathione S-transferase P1 polymorphism. Egypt J Med Hum Genet. 2020;21(1):1–5.

  13. Abbas M, Verma S, Verma S, Siddiqui S, Khan FH, Raza ST, et al. Association of GSTM1 and GSTT1 gene polymorphisms with COVID‐19 susceptibility and its outcome. J Med Virol. 2021

  14. Coric V, Milosevic I, Djukic T, Bukumiric Z, Savic-Radojevic A, Matic M, et al. GSTP1 and GSTM3 variant alleles affect susceptibility and severity of COVID-19. Front Mol Biosci. :1169.

  15. Ali-Osman F, Akande O, Antoun G, Mao J-X, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants: evidence for differential catalytic activity of the encoded proteins. J Biol Chem. 1997;272(15):10004–12.

  16. Di Pietro G, Magno LA V, Rios-Santos F. Glutathione S-transferases: an overview in cancer research. Expert Opin Drug Metab Toxicol. 2010;6(2):153–70.

  17. Tabary M, Khanmohammadi S, Araghi F, Dadkhahfar S, Tavangar SM. Pathologic features of COVID-19: A concise review. Pathol Pract. 2020;153097.

  18. Astuti I. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):407–12.

  19. Mokhtari T, Hassani F, Ghaffari N, Ebrahimi B, Yarahmadi A, Hassanzadeh G. COVID-19 and multiorgan failure: A narrative review on potential mechanisms. J Mol Histol. 2020;1–16.

  20. Saadat M. An evidence for correlation between the glutathione S-transferase T1 (GSTT1) polymorphism and outcome of COVID-19. Clin Chim Acta. 2020;508:213.

  21. Thyagaraju K, Hemavathi B, Vasundhara K, Rao AD, Devi KN. Comparative study on glutathione transferases of rat brain and testis under the stress of phenobarbitol and β-methylcholanthrene. J Zhejiang Univ Sci B. 2005;6(8):759–69.

  22. Wang S, Yang J, You L, Dai M, Zhao Y. GSTM3 Function and Polymorphism in Cancer: Emerging but Promising. Cancer Manag Res. 2020;12:10377.

  23. Flamant C, Henrion-Caude A, Boëlle P-Y, Brémont F, Brouard J, Delaisi B, et al. Glutathione-S-transferase M1, M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis. Pharmacogenet Genomics. 2004;14(5):295–301.

  24. Çalışkan M, Baker SW, Gilad Y, Ober C. Host genetic variation influences gene expression response to rhinovirus infection. PLoS Genet. 2015;11(4):e1005111.

  25. van de Wetering C, Elko E, Berg M, Schiffers CHJ, Stylianidis V, van den Berge M, et al. Glutathione S-transferases and their implications in the lung diseases asthma and chronic obstructive pulmonary disease: Early life susceptibility? Redox Biol. 2021;101995.

  26. Qi L, Zou Z-Q, Wang L-Y, Gao S, Fan Y-C, Long B, et al. Methylation of the glutathione-S-transferase M3 gene promoter is associated with oxidative stress in acute-on-chronic hepatitis B liver failure. Tohoku J Exp Med. 2012;228(1):43–51.

Published
2023/05/18
Issue
Vol. 74 No. 1 (2023): Medicinski podmladak
Section
Original Scientific Paper